Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical
antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it …

Objective Clozapine is substantially underutilized in most countries and clinician factors
including lack of knowledge and concerns about adverse drug effects (ADEs) contribute …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Background Clozapine remains the only medication licensed for treating refractory
schizophrenia. However, it remains underutilized in part due to concerns regarding adverse …

Clozapine is vital for managing schizophrenia and other psychiatric disorders. As a potent
medication with risks of severe side effects, accurate detection ensures effective treatment …

Objectives: Rechallenge/continuation of clozapine in association with colony-stimulating
factors (CSFs) following neutropenia/agranulocytosis has been reported, but many …

Background: Clozapine is the most effective medication for treatment-refractory
schizophrenia; however, its use is contraindicated in people who have had previous …

Clozapine remains the only drug treatment likely to benefit patients with treatment resistant
schizophrenia. Its use is complicated by an increased risk of neutropenia and so there are …

Use of the atypical antipsychotic clozapine is associated with life-threatening
agranulocytosis. The delayed onset and the association with HLA variants are characteristic …

Objective: Clozapine remains the most effective intervention for treatment resistant
schizophrenia; however, its use is prohibited following neutropenias. We review neutrophil …